BioPharma Dive September 9, 2024
Sponsored content By Quest Diagnostics
The relentless impact of Alzheimer’s disease (AD) on individuals, families, and societies worldwide is staggering. As a clinician and researcher in the field of neurology and neuroimmunology, I have witnessed firsthand the profound effects of this debilitating disease. But I’ve also seen remarkable innovations and strides in diagnostics that give us reason for hope.
In a recently published white paper titled “Accelerating Alzheimer’s Therapy Innovation: The Power of Blood-Based Biomarkers,” I’ve had the opportunity to explore and discuss the potential of blood-based biomarkers in the ongoing battle against AD.
A Global Challenge
With AD affecting nearly 60-80% of the 55 million global dementia cases and expected to grow to 140 million by 2050, the burden...
Today's Sponsors
Today's Sponsor